Programme

09:30 TS-01-01
From renal physiology to therapeutic innovation: Laying the foundations for SGLT2 inhibition
Volker Vallon, San Diego, USA

10:00 TS-01-02
Cardiovascular protection by SGLT2 inhibition: Emerging mechanisms beyond glucose lowering
Coert J. Zuurbier, Amsterdam, Netherlands

10:20 TS-01-03
Insights into SGLT2 inhibition in metabolic dysfunction-associated steatotic liver disease: Current status and future directions
Susanne Kaser, Innsbruck, Austria

10:40 TS-01-04
SGLT2 inhibition, brain metabolism and neurodegeneration: Emerging concepts
Monica Garcia-Alloza, Cadiz, Spain

Short description:
Sodium–glucose cotransporter 2 (SGLT2) is a key mediator of renal glucose reabsorption in the proximal tubule. In diabetes, enhanced SGLT2 activity contributes to maladaptive renal glucose retention, thereby aggravating hyperglycemia. Pharmacological inhibition of SGLT2 was therefore initially developed as a glucose-lowering strategy. Unexpectedly, large clinical trials subsequently revealed robust renal and cardiovascular benefits that extend beyond glycemic control. Emerging evidence further suggests roles of SGLT2 inhibition in hepatic and neural systems. Despite these advances, the precise mechanisms through which SGLT2 inhibition protects multiple organs remain to be fully elucidated. Accordingly, this symposium is structured around the central question: how targeting renal glucose transport can confer protective effects beyond the kidney. It brings together experimental and clinical perspectives on SGLT2 inhibition in the heart, liver, and brain.